Constellation pharma had a Bromodomain and Extra-Terminal (BET) protein inhibitor called Pelabresib for MF and MDS.Morphosys acquired Constellation for $1.7Bn in June 2021.Next Novartis acquired Morphosys in Feb 2024 for US $2.92 Bn (EUR $2.7 Bn)The focus of these acquisitions is the combined MF and MDS trial being trialled in combination with JAK inhibitor (Ruxolitinib)- https://clinicaltrials.gov/study/NCT02158858No.of patients: 336In the 1/7/24 preso slide 11, Gary has this transaction as successful phase 3- details of the trials here- https://clinicaltrials.gov/study/NCT04603495Syntara SNT-5505 in MF: https://clinicaltrials.gov/study/NCT04676529We are also doing a combination trial with the JAK inhibitor ruxolitinibNo.of patients: 39
From the looks of it, Constellation’s and Syntara’s MF trials have similar endpoints (at a high level) although vastly different patient populations.So yes, at the December readout we may be in the crosshairs of some BPs.AIMO. DYOR.
- Forums
- ASX - By Stock
- SNT - Research & Valuation
Constellation pharma had a Bromodomain and Extra-Terminal (BET)...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.2¢ |
Change
0.005(10.6%) |
Mkt cap ! $71.40M |
Open | High | Low | Value | Volume |
4.8¢ | 5.4¢ | 4.6¢ | $176.7K | 3.467M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 225623 | 5.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.2¢ | 120442 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 225623 | 0.051 |
2 | 309996 | 0.050 |
1 | 19998 | 0.049 |
3 | 121996 | 0.048 |
1 | 120000 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.052 | 120442 | 2 |
0.054 | 53415 | 2 |
0.055 | 115000 | 2 |
0.057 | 257052 | 2 |
0.060 | 117667 | 2 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |